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TO THE EDITOR
Pure hair and nail ectodermal dysplasia
(PHNED; OMIM 602032) is a con-
genital disorder characterized by
hypotrichosis and nail dystrophy. The
disease can show either an autosomal
dominant (Barbareschi et al., 1997) or
autosomal recessive (Calzavara-Pinton
et al., 1991) inheritance pattern. The
autosomal recessive form has been
mapped to chromosome 17p12–q21.2
(Naeem et al., 2006a) and 12p11.1–
q21.1 (Naeem et al., 2006b, 2007),
which contain the type I and type II
keratin clusters, respectively. One
homozygous mutation in a type II hair
keratin gene KRT85, previously known
as hHb5, was recently identified in
a consanguineous Pakistani family with
autosomal recessive PHNED (Naeem
et al., 2006b). However, the clinical
characteristics and the molecular basis
of the disease have been poorly under-
stood to date. In this study, we identi-
fied two consanguineous Pakistani
families with PHNED and found two
distinct homozygous mutations in the
KRT85 gene in both families.
We analyzed two consanguineous
Pakistani families, designated as Families
A and B, with several affected indivi-
duals. Both families show autosomal
recessive inheritance of the disease
trait (Figure 1a). All affected individuals
in both families have shown hypotricho-
sis and nail dystrophy since birth, but
there is a difference in severity between
the two families. In Family A, all affected
individuals show sparse hair and
diffuse follicular papules on the scalp
(Figure 1b-d). Facial and body hair is
less dense overall. In addition, distal
ends of nails are irregularly shaped
and break easily (Figure 1e). It is
noteworthy that the patients’ scalp hair
shows fragility. Scanning electron micro-
scopy showed that the thickness of
the hair shaft was inconsistent (Figure
1f). The variation in hair diameter did not
show a periodic pattern as observed in
monilethrix hair (Ito et al., 1990). Never-
theless, it suggests abnormal keratiniza-
tion of the hair shaft. As compared with
Family A, affected individuals in Family
B show a more severe phenotype. They
display complete alopecia with diffuse
follicular papules on the scalp (Figure
1g). Facial and body hairs are also
absent. Furthermore, the tips of nails
show severe deformities (Figure 1h).
Affected individuals in both families
show normal facial features, teeth, and
sweating, and do not show palmoplantar
hyperkeratosis.
After obtaining informed consent,
we collected peripheral blood samples
from members of both families and 100
population-matched unrelated healthy
control individuals in EDTA-containing
tubes (under institutional approval
and in adherence to the Declaration
of Helsinki Principles). Genomic DNA
was isolated from these samples accor-
ding to standard techniques. On the
basis of the clinical features, we diag-
nosed both families as PHNED. We first
performed genotyping using micro-
satellite markers around the type I
keratin cluster on chromosome 17q21
and type II keratin cluster on chromo-
some 12q13. The results excluded
linkage to the type I keratin cluster in
both families (data not shown), and
suggested linkage of both families
to the type II keratin cluster (Figure
1a). In particular, critical recombina-
tion events were detected between
markers D12S398 and D12S1618 in
affected individual IV-1 of family A, as
well as between markers D12S368 and
D12S398 in unaffected individual III-2
of family A, which allowed the interval
of linkage to be narrowed to 1.26 Mb
flanked by markers D12S368 and
D12S1618 (Figure 1a). The KRT85 gene
resides in this region.
We next sequenced the KRT85
gene in affected individuals from both
families using gene-specific primers,
which were designed based on refer-
ence sequences (NCBI accession num-
ber: NG_008353). We identified
homozygous mutations in the KRT85 in
both families. All affected individuals in
Family A are homozygous for a deletion
mutation c.1448_1449delCT in exon 9
of the KRT85 gene, which was not
reported previously and is predicted to
result in a frameshift at codon 483 and a
premature termination codon 18 amino
acid residues downstream of the muta-
tion (p.Pro483ArgfsX18) (Figure 2a, b).
Screening assays with the restriction
enzyme NlaIV confirmed that the muta-
tion completely co-segregates with the
disease phenotype, and 100 healthy
control individuals from Pakistan do
not carry the mutation (data not shown).
Since the mutation is located within the
last exon of the KRT85 gene, aberrant
transcripts with the PTC may be ex-
pressed, and a truncated K85 protein
would be generated. The altered amino
acid sequences in C-terminus of the
mutant K85 protein are largely different
from those of the wild-type K85 protein.
In particular, the mutant protein lacks
two cysteine residues at amino acid
positions 489 and 498 (Figure 2b).
Therefore, the mutant protein with an
abnormal tail domain would deleter-
iously affect heterodimer formation.
The affected individual in Family B
is homozygous for a G-to-A substitu-
tion at position 233 in exon 1 of the
KRT85 gene (c.233G4A), which leads
to the transition from arginine to
histidine at amino acid position 78
(p.Arg78His) (Figure 2c). This mutation
was previously identified in a Pakistani
family with PHNED, which shows
complete alopecia and severe nail
dystrophy (Naeem et al., 2006b).
It is noteworthy that Family B also
exhibits severe hair and nail pheno-
types, which may suggest that the
mutation p.Arg78His would disrupt
the function of the K85 protein
more severely than the mutation
p.Pro483ArgfsX18. Including the two
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families in this report, only three
families with two distinct KRT85 muta-
tions have been identified. Additional
cases with KRT85 mutations will be
required to determine clear genotype–-
phenotype correlations.
The K85 protein is abundantly
expressed in the matrix, precortex,
cortex, and cuticle of the hair shaft
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Figure 1. Pedigrees and clinical appearance of two Pakistani families with PHNED. (a) Pedigrees and results of haplotype analysis. The linked haplotypes are
indicated in red, and critical recombination events are indicated by arrows. (b–e) Clinical features of affected individuals in Family A. (f) SEM observation of hair
of an affected individual in Family A. Bar¼ 100mm. (g, h) Clinical features of affected individuals in Family B. Note that affected individuals in Family B show a
more severe phenotype than those in Family A.
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(Langbein et al., 2001), as well as
in the keratogenous zone of the nail
matrix (Perrin et al., 2004). The keratins
form the intermediate filaments that
anchor to desmosomal components
and maintain the tissue integrity
(Coulombe and Omary, 2002). We
postulate that dysfunction of K85
protein would lead to disruption of
keratin intermediate filament formation
and abnormal desmosomal assembly
in hair and nails. Our findings not
only expand the limited spectrum of
KRT85 mutations but also underscore
the crucial role of K85 in the
keratinization of hair and nails in
humans.
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Figure 2. Identification of mutations in the KRT85 gene. (a) A novel homozygous mutation c.1448_1449delCT (p.Pro483ArgfsX18) in the KRT85
gene in Family A. The deleted nucleotides are boxed. (b) Comparison of amino acid sequences between wild-type and the mutant K85 proteins with
the mutation p.Pro483ArgfsX18. Amino acid position 483, where the frameshift occurs, is indicated by an arrow. Cysteine residues at positions 489
and 498 in wild-type protein are in blue. Asterisks, stop codon. (c) A homozygous mutation c.233G4A (p.Arg78His) in the KRT85 gene
in Family B.
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TO THE EDITOR
Although different authors have con-
firmed the involvement of T cells in
delayed-type hypersensitivity reactions
to glucocorticosteroids (GCs) in skin
biopsies (Padial et al., 2005) or by
specific lymphocyte responses (Buettiker
et al., 2006), the underlying mechanisms
are complex, because both the antiin-
flammatory and pro-allergic effects may
take place at the same time.
Dendritic cells (DCs) are central to
the development of specific effector
and tolerant immunological responses
(Steinman et al., 2003). Low-molecular-
weight compounds, including drugs,
are able to induce DC maturation
(Manome et al., 1999; Rodriguez-Pena
et al., 2006), which could be respon-
sible for the loss of tolerance to these
molecules. However, some drugs, such
as GCs, can inhibit the generation of
mature DCs (Pan et al., 2001), thereby
hindering the evaluation of the way this
drug is involved in delayed-type hyper-
sensitivity reactions.
We report a 40-year-old man
with rhinoconjunctivitis sensitized to
pollens, who developed a generalized
exanthema 5 days after starting treat-
ment with nasal budesonide (Rhinocort,
Astra, Lund, Sweden) and 8 hours after
the last inhalation. A patch test was
positive with budesonide and the skin
biopsy showed a perivascular mono-
nuclear cell infiltrate, with the presence
of CD4þ and, to a lesser degree,
CD8þ cells, detected by immunohisto-
chemistry. These cells were memory
cells (CD45ROþ ), with a moderate
expression of the activation marker
CD25. Patch and drug provocation tests
were negative with dexamethasone,
beclomethasone, methylprednisolone,
and hydrocortisone.
In this patient and in five healthy
nonallergic controls who tolerated the
drug, we analyzed the in vitro immuno-
logical response to different GCs by
culturing autologous lymphocytes with
and without monocyte-derived DCs
(mo-DCs) and evaluated the specific
lymphocyte proliferation, their activa-
tion markers, and the changes in the
maturational phenotype of DCs.
Peripheral blood mononuclear cells
were isolated and cultivated in complete
medium (RPMI-1640 medium with 10%
autologous serum). The nonadherent
cells containing lymphocytes were fro-
zen for future use, and the adherent cells
(monocytes) were cultured in 2 ml of
complete medium supplemented with
GM-CSF (R&D System, Minneapolis,
MN) (800 U ml1) and IL-4 (R&D
System) (500 U ml1) for 4 days to obtain
mo-DCs.
For proliferation assays, lympho-
cytes were cultured in 96-well plates
in triplicate, with or without mo-DCs
(150,000 lymphocytes and 15,000 DCs
per well), and with budesonide,
methylprednisolone, and hydrocorti-
sone at 10mg ml1, 0.1 mg ml1, and
0.001mg ml1, respectively. After 6
days, 3H-Thymidine incorporation was
evaluated in a b-counter as counts per
minute. The stimulation index (SI) was
calculated as the ratio of the mean
counts per minute of a drug-stimulated
sample to the mean counts per minute
of the sample alone. An SI43 was
considered positive.
For phenotype analysis, a panel
of mAbs (HLA-DR-FITC, CD86-FITC,
CD80-PE CD40-PE, and CD83-PE
for mo-DC, and CD4-FITC, CD25-PE,
HLA-DR-PE, CD3-PerCP, and CD8-APC
for lymphocytes) and an FACSCalibur
cytometer were used.
In the patient, lymphocyte prolifera-
tion tests were positive only with
budesonide (SI¼ 3.4), although higher
in the presence of mo-DCs (SI¼ 6.8),
and in both cases, only at the lowest
drug concentration (0.001mg ml1).
Abbreviations: DC, dendritic cell; GC, glucocorticosteroid; mo-DC, monocyte-derived dendritic cell; SI,
stimulation index
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